[Business Wire] – Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc. concerning possible violations of federal securities laws. Read more on this. Alexion Pharmaceuticals, Inc. (ALXN) , with a current value of $30.94B, opened at $140.00. Looking at the stock, its one day range is $136.14 to $140.75 with a trailing 52-week range being $124.16 to $208.88. ALXN shares are currently priced at 30.69x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.21x forward p/e ratio. According to a consensus of 20 analysts, the earnings estimate of $1.18 per share would be $0.26 worse than the year-ago quarter and a $0.06 sequential decrease. The full-year EPS estimate is $5.05, which would be a $0.06 better than last year. The quarterly earnings estimate is predicated on a consensus revenue forecast of $742.68 Million. If reported, that would be a 16.74% increase over the year-ago quarter. More recently, Robert W. Baird downgraded ALXN from Outperform to Neutral (Mar 8, 2016). Previously, Citigroup Initiated ALXN at to Buy. Investors should keep in mind is that the average price target is $193.22, which is 38.01% above where the stock opened this morning. See more in (NASDAQ:ALXN) Similar Articles: Stock Update (NASDAQ:GILD): SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc. Stock Update (NASDAQ:BIIB): SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Biogen Inc. Market Update (NYSE:CI): SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Cigna Corp.